These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 14571813

  • 1. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 3. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Mar; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 4. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 Mar; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Mar; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 6. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 7. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Aug; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 9. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L, Takács T, Babarczy E, Dux L, Lonovics J.
    Orv Hetil; 1997 Nov 23; 138(47):2981-5. PubMed ID: 9432648
    [Abstract] [Full Text] [Related]

  • 10. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992 Nov 23; 12(5):1687-93. PubMed ID: 1332581
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.
    Gastroenterol Hepatol; 1999 Nov 23; 22(7):335-41. PubMed ID: 10535205
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
    Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, Inoue K, Nakahara K.
    Hepatogastroenterology; 2002 Nov 23; 49(45):740-5. PubMed ID: 12063982
    [Abstract] [Full Text] [Related]

  • 16. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Bützow GH, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M.
    Hepatogastroenterology; 1985 Jun 23; 32(3):141-5. PubMed ID: 2410346
    [Abstract] [Full Text] [Related]

  • 17. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J, Arkosy P, Lenkey A, Sápy P.
    Acta Chir Hung; 1997 Jun 23; 36(1-4):125-7. PubMed ID: 9408313
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS.
    Gan To Kagaku Ryoho; 1989 Apr 23; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [Abstract] [Full Text] [Related]

  • 20. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993 Apr 23; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.